Can a routine shot at the pharmacy help protect your brain?
In this large study of US Medicare claims, adults age 65 and older who completed both doses of the recombinant zoster vaccine (Shingrix) had a 33% lower rate of new dementia over the first three years than matched unvaccinated adults. Alzheimer’s disease risk was 28% lower and vascular dementia risk was 33% lower over that same period. This was an observational look back at insurance records, not a randomized trial.
The shingles vaccine is given to prevent the painful rash caused by reactivation of the varicella zoster virus. Researchers have been asking a separate question about it for several years now: does preventing shingles also lower the risk of dementia? Earlier population-based studies in US veterans and in US adults with private health insurance found lower dementia rates after herpes zoster vaccination, with hazard ratios ranging from 0.65 to 0.75. This new analysis tested the recombinant vaccine specifically, in the Medicare population.
What the data show
The researchers used Medicare records to compare two groups of US adults age 65 and older. One group of 502,845 people had received both doses of the recombinant zoster vaccine. The second group of 1,005,690 people had not been vaccinated. Each vaccinated person was matched to two unvaccinated people on age, sex, and race or ethnicity. Everyone had to be enrolled in Medicare for at least 11 months before their start date and free of any pre-existing dementia diagnosis.
The vaccinated group developed dementia at a rate of 10.45 cases per 1,000 person-years. The unvaccinated group developed it at 15.73 cases per 1,000 person-years. In the models, the hazard ratio for new dementia was 0.67 during the first three years of follow-up and 0.74 beyond three years. For Alzheimer’s disease it was 0.72 and then 0.83. For vascular dementia it was 0.67 and then 0.66, so the vascular signal did not fade with longer follow-up.
Dr. Kumar’s Take
I find this study genuinely encouraging, and I want to be clear about both why and where I hold back. The effect size is large, and a one-third reduction in new dementia would be transformative if it holds up. I have very few tools that move dementia risk at all. But this is an observational study built from claims data, not a randomized trial. People who show up for a two-dose vaccine series tend to be more engaged with their health in general, and that engagement is itself linked to better brain aging. The authors matched on age, sex, and race or ethnicity, which balances the demographics but does not balance health behavior. I also note that the study was funded by GSK, which makes the vaccine, and that several authors work there. That does not make the result wrong, and the analysis is a serious one, but it belongs in your reading of it. What moves me toward optimism is that earlier large studies in veterans and in privately insured adults pointed the same direction. For my patients in their 60s and 70s, this is one more reason to take the vaccine seriously, on top of the reason that already existed: not getting shingles.
How the study was done
This was a retrospective cohort study, meaning the researchers looked back at existing Medicare claims rather than assigning anyone to treatment. Vaccinated people entered the analysis on the date of their second dose. Unvaccinated people entered on the date of a preventive care visit, which is a deliberate choice: it compares vaccinated adults against other adults who were also showing up for routine care. Matching was one vaccinated person to two unvaccinated people on age, sex, and race or ethnicity, and weighted Cox proportional hazards models generated the hazard ratios. The team also reran the analysis using 3-month and 6-month induction periods, discarding dementia diagnoses that appeared very soon after the index date, and those analyses supported the main result. Claims data can only capture what was coded, and matching on demographics cannot remove differences the records never recorded.
Why this might work
The biology here is still open. The authors are direct that the cause of dementia is unclear, and that the evidence linking herpes zoster infection itself to dementia risk has been mixed: some studies report a strong association, some a mild one, and at least one found none. The working idea behind this line of research is that if reactivation of the varicella zoster virus contributes to the injury that leads to dementia, then preventing reactivation should lower the risk. This study tested the risk, not the mechanism. Anyone claiming to know exactly how a vaccine would protect the brain is ahead of the data.
Practical Takeaways
- If you are 65 or older and have not completed the two-dose recombinant zoster vaccine series, this study is a reason to raise it with your doctor or pharmacist, alongside the established reason of preventing shingles.
- The finding applies to the two-dose series completed. Both doses matter here, since the analysis started counting from the date of the second dose.
- Treat this as one line of evidence, not a decision made. It is observational, and a randomized trial designed to test the brain question has not been done.
- If you have a weakened immune system or a history of severe reactions to vaccines, discuss timing and safety with your doctor before scheduling the shots.
Related Studies and Research
- Shingles vaccine cuts heart attack risk nearly in half for heart disease patients
- A gentle Chinese exercise lowers blood pressure as well as brisk walking
- Eating eggs regularly linked to lower Alzheimer’s risk in older adults
- Being physically fit lowers your risk of depression and dementia
FAQs
Does this study prove the shingles vaccine prevents dementia?
No. This is a large, carefully constructed observational study, but it cannot establish cause and effect the way a randomized trial can. The people who completed a two-dose vaccine series may differ from those who did not in ways that Medicare claims never record, and any of those differences could contribute to lower dementia rates. What the study does well is add a very large data point to a body of evidence that keeps producing the same answer. A randomized trial designed specifically around the brain-health question is still the missing piece.
Is it too late to benefit if I am already in my late 70s or 80s?
Everyone in this analysis was at least 65 years old at their start date. What I cannot tell you from this design is the point at which a first vaccination stops shifting risk. In practice, the limiting factors at older ages are how well your immune system responds and your overall medical stability, which are worth discussing directly with your doctor rather than guessing at.
Could vaccinated people simply have been healthier to begin with?
That is the central worry with any study like this, and the authors took two steps against it. First, they matched each vaccinated person to two unvaccinated people on age, sex, and race or ethnicity. Second, they anchored the unvaccinated group to the date of a preventive care visit, so the comparison group was also engaged enough with the health system to show up for routine care. They also reran the analysis excluding dementia diagnoses made within 3 and 6 months of the start date, and the lower risk persisted. None of that fully rules out that vaccinated adults were healthier in ways the claims data cannot see.
Bottom Line
Among 502,845 Medicare beneficiaries age 65 or older who completed the two-dose recombinant zoster vaccine series and 1,005,690 matched unvaccinated beneficiaries, new dementia occurred at 10.45 versus 15.73 cases per 1,000 person-years. The hazard ratio was 0.67 within the first three years and 0.74 after, with similar reductions for Alzheimer’s disease and vascular dementia. This is observational evidence and cannot substitute for a randomized trial, but it is a very large analysis pointing the same way as earlier ones. The vaccine is already worth getting to prevent shingles, and the brain-health signal strengthens the case.
